0000899243-21-036399.txt : 20210917 0000899243-21-036399.hdr.sgml : 20210917 20210917133841 ACCESSION NUMBER: 0000899243-21-036399 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210915 FILED AS OF DATE: 20210917 DATE AS OF CHANGE: 20210917 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pfeffer Cary CENTRAL INDEX KEY: 0001591092 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37998 FILM NUMBER: 211259858 MAIL ADDRESS: STREET 1: C/O ELEVEN BIOTHERAPEUTICS STREET 2: 215 FIRST STREET, SUITE 400 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Jounce Therapeutics, Inc. CENTRAL INDEX KEY: 0001640455 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 454870634 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-259-3840 MAIL ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-09-15 0 0001640455 Jounce Therapeutics, Inc. JNCE 0001591092 Pfeffer Cary C/O THIRD ROCK VENTURES, LLC, 29 NEWBURY STREET, 3RD FLOOR BOSTON MA 02116 1 0 0 0 Common Stock 2021-09-15 4 J 0 0 D 0 I See footnote Common Stock 0 I See footnote Common Stock 50468 D Pursuant to a 10b5-1 trading plan adopted on November 18, 2020 by Third Rock Ventures II, L.P. ("TRV II"), TRV II distributed for no consideration, 1,750,000 shares of Common Stock of the Issuer (the "Shares") on September 15, 2021, to its limited partners and to Third Rock Ventures GP II, L.P. ("TRV GP II"), the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. After the reported transaction, TRV II directly holds 2,697,829 shares of Common Stock. The Reporting Person is a partner of TRV GP II, which is the general partner of TRV II. The Reporting Person disclaims beneficial ownership over the 2,697,829 shares held by TRV II, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Third Rock Ventures III, L.P. ("TRV III") directly holds 3,048,780 shares of the Issuer's Common Stock. The Reporting Person is a partner of Third Rock Ventures GP III, L.P., which is the general partner of TRV III. The Reporting Person disclaims beneficial ownership over the shares held by TRV III, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. The shares are directly held by the Reporting Person. Includes Shares received in the distributions described in footnote (1) above. /s/ Cary Pfeffer 2021-09-17